{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["70(6)"],"submitter":["Furie RA"],"funding":["GlaxoSmithKline"],"pubmed_abstract":["Objective
We undertook this US multicenter continuation study (GlaxoSmithKline study BEL112233; ClinicalTrials.gov identifier: NCT00724867) to assess long-term safety and efficacy of belimumab in patients with systemic lupus erythematosus (SLE) who completed the Study of Belimumab in Subjects with SLE 76-week trial (ClinicalTrials.gov identifier: NCT00410384).Methods
Patients continued to receive the same belimumab dose plus standard therapy; patients previously receiving placebo received 10 mg/kg belimumab. The primary outcome measure was long-term safety of belimumab (frequency of adverse events [AEs] and damage assessed using the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index [SDI], evaluated every 48 weeks [1 study year]"],"journal":["Arthritis & rheumatology (Hoboken, N.J.)"],"pagination":["868-877"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6001779"],"repository":["biostudies-literature"],"pubmed_title":["Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States."],"pmcid":["PMC6001779"],"pubmed_authors":["Aranow C","Wilson B","Wallace DJ","Roth DA","Furie RA","Gordon D","Fettiplace J","Mistry P"],"additional_accession":[]},"is_claimable":false,"name":"Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States.","description":"Objective
We undertook this US multicenter continuation study (GlaxoSmithKline study BEL112233; ClinicalTrials.gov identifier: NCT00724867) to assess long-term safety and efficacy of belimumab in patients with systemic lupus erythematosus (SLE) who completed the Study of Belimumab in Subjects with SLE 76-week trial (ClinicalTrials.gov identifier: NCT00410384).Methods
Patients continued to receive the same belimumab dose plus standard therapy; patients previously receiving placebo received 10 mg/kg belimumab. The primary outcome measure was long-term safety of belimumab (frequency of adverse events [AEs] and damage assessed using the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index [SDI], evaluated every 48 weeks [1 study year]","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Jun","modification":"2026-04-07T20:02:16.488Z","creation":"2025-05-29T21:18:39.716Z"},"accession":"S-EPMC6001779","cross_references":{"pubmed":["29409143"],"doi":["10.1002/art.40439"]}}